Technology

CytomX

$6.87
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.04 (+0.58%) Today
-$0.07 (-0.95%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell CytomX and other stocks, options, and ETFs commission-free!

About CTMX

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA. The listed name for CTMX is CytomX Therapeutics, Inc. Common Stock.

CEO
Sean A. McCarthy
Employees
158
Headquarters
South San Francisco, California
Founded
2010
Market Cap
298.21M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.65M
High Today
$7.34
Low Today
$6.77
Open Price
$7.04
Volume
1.94M
52 Week High
$15.44
52 Week Low
$3.60

Collections

CTMX Earnings

-$0.79
-$0.44
-$0.09
$0.26
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, After Hours

You May Also Like

EMAN
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure